心力衰竭
中医药
医学
黄芪
药理学
血管生成
纤维化
药品
心脏纤维化
心肌肥大
传统医学
心脏病学
内科学
病理
替代医学
作者
Yibei Zang,Jingjing Wan,Zhen Zhang,Si Huang,Xia Liu,Weidong Zhang
标识
DOI:10.1016/j.biopha.2020.110012
摘要
Heart failure (HF) has become a worldwide public health problem that seriously threatens human’s health. Due to "multi-target" effect, traditional Chinese medicine (TCM) has unique advantages in this field. Chinese herb-derived active components would provide valuable candidate compounds for new drug development. Astragaloside IV(AS-IV) is a main effective ingredient of Astragalus membranaceus, a commonly used Chinese patent medicine for the patients with chronic heart failure(CHF). Our aim is to review the recent progresses of AS-IV in HF, and provide potential evidence for its clinical application. Data showed that AS-IV could protect myocardial ischemia, regulate sarcoplasmic reticulum Ca2+ pump, promote angiogenesis, improve energy metabolism, inhibit cardiac hypertrophy and fibrosis, reduce myocardial cell apoptosis, etc, which are direct or indirect involved in the beneficial effects of AS-IV in rodents or cellular models of HF. AS-IV or its derivatives may act as a potential therapeutic drug in the clinical treatment of HF.
科研通智能强力驱动
Strongly Powered by AbleSci AI